Keryx Biopharmaceuticals Announces Second Quarter 2015 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/13/2026
- S&P 500 ends higher as strong inflation data cements rate-hike bets
- Oracle raises full year profit guidance, stock rises after hours
- Oil falls but head for 8% weekly gain on tight supply; US diesel hits record
- 'No panic anywhere' may be the problem, BofA strategists warn
- Buy Shopify stock at this ’AI-enabled entry point,’ analyst says
- After-Hours Movers: ORCL, CRWV, ADBE, ACVA, CPRT, ZUMZ, PMTS, RH
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
BTIG Cuts Keryx Biopharmaceuticals (KERX) to Sell
August 6, 2015 10:01 AM EDTBTIG earlier downgraded Keryx Biopharmaceuticals (NASDAQ: KERX) from Neutral to Sell with a price target of $3.50. The change follows Q2 results. Analyst Hartaj Sing pointed out revenue weakness.
"We are downgrading Keryx from a Neutral to a Sell with a $3.50 price target after the... More
Keryx Biopharmaceuticals (KERX) PT Cut to $22 at Brean Capital Following Q2; Upside Seen Over 200%
August 5, 2015 12:06 PM EDTBrean Capital analyst Jonathan Aschoff lowered his price target on Keryx Biopharmaceuticals (NASDAQ: KERX) to $22.00 (from $26.00) following Q2 results but maintained a Buy rating as the new price target still suggests 224% upside from current levels. The analyst expects more meaningful Auryxia sales to come in 2H15.
Aschoff commented, "Keryx reported 2Q15 total revenue of $2.5 million, versus consensus of $2.9 million, but we expect more... More
Keryx Biopharma (KERX) Reports In-Line Q2 EPS
August 5, 2015 7:17 AM EDTKeryx Biopharma (NASDAQ: KERX) reported Q2 EPS of ($0.26), in-line with the analyst estimate of ($0.26). Revenue for the quarter came in at $2.5 million versus the consensus estimate of $2.86 million.
"We are making progress on several important milestones across our business, including securing broad reimbursement for Auryxia (ferric citrate) that today enables... More
